# Definium Therapeutics Inc. (DFTX)

Source: https://www.quantisnow.com/company/DFTX
Generated: 2026-11-22T17:07:44.857Z

- Ticker: DFTX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medicinal Chemicals and Botanical Products
- SEC CIK: 0001813814

## Latest DFTX news and filings

- 2026-11-16 18:15 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-definium-therapeutics-inc-6793628)
- 2026-11-13 18:51 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-definium-therapeutics-inc-6790082)
- 2026-11-09 21:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Definium Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-definium-therapeutics-inc-6781508)
- 2026-11-09 21:10 UTC [SEC Form 8-K] [Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/definium-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6781360)
- 2026-11-09 21:01 UTC [Earnings] [Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights](https://www.quantisnow.com/insight/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-6781025)
- 2026-11-09 12:01 UTC [Definium Therapeutics Announces New Employee Inducement Grants](https://www.quantisnow.com/insight/definium-therapeutics-announces-new-employee-inducement-grants-6780116)
- 2026-11-05 18:16 UTC [SEC Schedule 13G] [SEC Form SCHEDULE 13G filed by Definium Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-definium-therapeutics-inc-6775528)
- 2026-11-04 12:00 UTC [Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress](https://www.quantisnow.com/insight/definium-therapeutics-presents-topline-phase-3-data-for-dt120-odt-6771199)
- 2026-11-03 12:01 UTC [Definium Therapeutics to Participate at Upcoming Investor Conferences](https://www.quantisnow.com/insight/definium-therapeutics-to-participate-at-upcoming-investor-conferences-6768394)
- 2026-10-29 20:01 UTC [Earnings Date] [Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026](https://www.quantisnow.com/insight/definium-therapeutics-to-report-third-quarter-2026-financial-results-on-6763283)
- 2026-10-26 20:01 UTC [Definium Therapeutics Announces New Employee Inducement Grants](https://www.quantisnow.com/insight/definium-therapeutics-announces-new-employee-inducement-grants-6757458)
- 2026-10-13 20:01 UTC [Definium Therapeutics Announces New Employee Inducement Grants](https://www.quantisnow.com/insight/definium-therapeutics-announces-new-employee-inducement-grants-6744907)
- 2026-10-09 12:44 UTC [Analyst Coverage Initiated] [Analyst initiated coverage on Definium Therapeutics with a new price target](https://www.quantisnow.com/insight/analyst-initiated-coverage-on-definium-therapeutics-with-a-new-price-6742495)
- 2026-09-30 01:15 UTC [SEC Form 4] [Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)](https://www.quantisnow.com/insight/chief-medical-officer-karlin-daniel-sold-396894-worth-of-shares-6729701)
- 2026-09-30 01:14 UTC [SEC Form 4] [Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)](https://www.quantisnow.com/insight/chief-executive-officer-barrow-robert-sold-1153784-worth-of-shares-6729700)
- 2026-09-30 01:12 UTC [SEC Form 4] [Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)](https://www.quantisnow.com/insight/chief-commercial-officer-wiley-matthew-t-sold-113257-worth-of-6729698)
- 2026-09-30 01:10 UTC [SEC Form 4] [Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax](https://www.quantisnow.com/insight/chief-legal-officer-sullivan-mark-sold-513845-worth-of-shares-6729697)
- 2026-09-30 01:08 UTC [SEC Form 4] [Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)](https://www.quantisnow.com/insight/chief-financial-officer-roberts-brandi-sold-123497-worth-of-shares-6729695)
- 2026-09-28 20:01 UTC [Definium Therapeutics Announces New Employee Inducement Grants](https://www.quantisnow.com/insight/definium-therapeutics-announces-new-employee-inducement-grants-6728502)
- 2026-09-25 20:19 UTC [SEC Form 144] [SEC Form 144 filed by Definium Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-definium-therapeutics-inc-6726532)
- 2026-09-25 20:15 UTC [SEC Form 144] [SEC Form 144 filed by Definium Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-definium-therapeutics-inc-6726523)
- 2026-09-25 20:14 UTC [SEC Form 144] [SEC Form 144 filed by Definium Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-definium-therapeutics-inc-6726511)
- 2026-09-19 01:55 UTC [SEC Form 4] [Director Vallone Carol A exercised 1,086 shares at a strike of $35.52, increasing direct ownership by 5% to 22,296 units (SEC Form 4)](https://www.quantisnow.com/insight/director-vallone-carol-a-exercised-1086-shares-at-a-strike-6721032)
- 2026-09-19 01:55 UTC [SEC Form 4] [Director Krebs Andreas exercised 1,629 shares at a strike of $35.52, increasing direct ownership by 8% to 21,402 units (SEC Form 4)](https://www.quantisnow.com/insight/director-krebs-andreas-exercised-1629-shares-at-a-strike-of-6721031)
- 2026-09-14 12:30 UTC [SEC Form 4] [Chief Executive Officer Barrow Robert was granted 750,000 shares, increasing direct ownership by 50% to 2,244,640 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-barrow-robert-was-granted-750000-shares-increasing-6713869)
- 2026-09-14 12:30 UTC [SEC Form 4] [Chief Legal Officer Sullivan Mark was granted 125,000 shares, increasing direct ownership by 33% to 508,279 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-legal-officer-sullivan-mark-was-granted-125000-shares-increasing-6713867)
- 2026-09-14 12:30 UTC [SEC Form 4] [Chief Financial Officer Roberts Brandi was granted 125,000 shares, increasing direct ownership by 46% to 397,905 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-roberts-brandi-was-granted-125000-shares-increasing-6713866)
- 2026-09-14 12:30 UTC [SEC Form 4] [Chief Commercial Officer Wiley Matthew T. was granted 125,000 shares, increasing direct ownership by 53% to 362,133 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-commercial-officer-wiley-matthew-t-was-granted-125000-shares-6713865)
- 2026-09-14 12:30 UTC [SEC Form 4] [Chief Medical Officer Karlin Daniel was granted 200,000 shares, increasing direct ownership by 33% to 803,699 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-karlin-daniel-was-granted-200000-shares-increasing-6713864)
- 2026-09-14 12:02 UTC [SEC Form 8-K] [Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/definium-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6713826)
- 2026-09-14 11:00 UTC [Conference Announcement] [Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder](https://www.quantisnow.com/insight/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-6713658)
- 2026-09-14 10:00 UTC [Definium Therapeutics Announces New Employee Inducement Grants](https://www.quantisnow.com/insight/definium-therapeutics-announces-new-employee-inducement-grants-6713521)
- 2026-09-13 21:00 UTC [Conference Announcement] [Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026](https://www.quantisnow.com/insight/definium-therapeutics-to-discuss-topline-results-from-phase-3-panorama-6713490)
- 2026-09-08 12:00 UTC [SEC Form 8-K] [Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/definium-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6707589)
- 2026-09-08 11:00 UTC [Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results](https://www.quantisnow.com/insight/definium-therapeutics-receives-breakthrough-therapy-designation-for-dt120-lysergide-orally-6707370)
- 2026-09-05 01:30 UTC [SEC Form 4] [Chief Executive Officer Barrow Robert was granted 40,000 shares and sold $721,733 worth of shares (19,023 units at $37.94) as part of a pre-agreed trading plan, increasing direct ownership by 1% to 1,494,640 units (SEC Form 4) (tax withholding)](https://www.quantisnow.com/insight/chief-executive-officer-barrow-robert-was-granted-40000-shares-and-6707119)
- 2026-08-31 20:01 UTC [Definium Therapeutics Announces New Employee Inducement Grants](https://www.quantisnow.com/insight/definium-therapeutics-announces-new-employee-inducement-grants-6699639)
- 2026-08-26 11:01 UTC [Conference Announcement] [Definium Therapeutics to Participate at Upcoming Investor Conferences and Events](https://www.quantisnow.com/insight/definium-therapeutics-to-participate-at-upcoming-investor-conferences-and-events-6694934)
- 2026-08-18 12:22 UTC [Analyst Coverage Initiated] [BofA Securities initiated coverage on Definium Therapeutics with a new price target](https://www.quantisnow.com/insight/bofa-securities-initiated-coverage-on-definium-therapeutics-with-a-new-6685968)
- 2026-08-17 20:01 UTC [Definium Therapeutics Announces New Employee Inducement Grants](https://www.quantisnow.com/insight/definium-therapeutics-announces-new-employee-inducement-grants-6684843)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/DFTX
- Earnings history: https://www.quantisnow.com/earnings/DFTX
- Dividend history: https://www.quantisnow.com/dividends/DFTX
- Insider transactions: https://www.quantisnow.com/insiders/DFTX
- Options chain: https://www.quantisnow.com/options/DFTX
- SEC 8-K filings only: https://www.quantisnow.com/company/DFTX/8-k
- RSS and alerts for DFTX: https://www.quantisnow.com/docs/rss-feeds.md
